DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lialda (Mesalamine) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

LIALDA SUMMARY

LIALDA (mesalamine)
Delayed Release Tablets

Each LIALDA delayed release tablet for oral administration contains 1.2g 5-aminosalicylic acid (5-ASA; mesalamine), an anti-inflammatory agent.

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond 8 weeks has not been established.


See all Lialda indications & dosage >>

LIALDA NEWS HIGHLIGHTS

Media Articles Related to Lialda (Mesalamine)

Mesalamine Granules Maintain Remission In Ulcerative Colitis Patients Who Switch From Another 5-ASA
Source: Irritable-Bowel Syndrome News From Medical News Today [2008.10.08]

APRISO(TM) Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative Colitis
Source: Irritable-Bowel Syndrome News From Medical News Today [2008.11.04]

APRISO™ Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative Colitis
Source: Irritable-Bowel Syndrome News From Medical News Today [2008.11.03]

more >>

Published Studies Related to Lialda (Mesalamine)

Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. [2007.01]

Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients. [2006.01]

more >>

Clinical Trials Related to Lialda (Mesalamine)

A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease [Completed]

Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis [Terminated]

The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels [Completed]

The CODA Study (Colitis Once Daily Asacol) [Recruiting]

Canadian Active & Maintenance Modified Pentasa Study [Recruiting]

more >>

Page last updated: 2008-11-04

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008